IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
October 03, 2023 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Second Quarter 2023 Financial Results
August 03, 2023 16:10 ET
|
IGM Biosciences, Inc.
– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., Aug. 03, 2023 ...
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 03, 2023 16:01 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of...
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
June 22, 2023 07:58 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its...
IGM Announces Proposed Public Offering and Concurrent Private Placement
June 21, 2023 17:17 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common...
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
June 02, 2023 17:30 ET
|
IGM Biosciences, Inc.
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months...
IGM Biosciences to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
May 31, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
May 30, 2023 07:00 ET
|
IGM Biosciences, Inc.
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology...